Does Medicaid Cover Foundayo? The Honest 2026 Answer

Last reviewed: March 27, 2026

The short version

Foundayo (orforglipron) received FDA approval for chronic weight management on April 1, 2026. Federal law makes weight-loss drug coverage optional for state Medicaid programs, and only 13 state Medicaid fee-for-service programs covered any GLP-1 for obesity as of January 2026 (KFF). We manually pulled seven current 2026 state preferred drug lists and found zero listings for Foundayo — including two PDLs revised after Foundayo’s FDA approval. Two states show early review signals.

That’s going to change. The CMS BALANCE Model opens a voluntary Medicaid coverage pathway starting as early as May 2026. Medicare Part D enrollees get a separate pathway July 1, 2026 at $50/month that includes Foundayo. But “opening” and “scheduled” aren’t “covered.”

The one-screen verdict

The straight answer: does Medicaid cover Foundayo?

Medicaid coverage for Foundayo depends on two things: the state you live in and the specific plan you’re enrolled in — because obesity-drug coverage is a category federal law lets state Medicaid programs exclude. As of April 20, 2026, Foundayo is not on the state Medicaid preferred drug lists we checked.

The answer isn’t “yes” or “no.” It’s “tell me your state and whether you’re on fee-for-service or a managed care organization, and I’ll tell you the actual next step.”

Is Foundayo on any Medicaid drug list yet?

No state Medicaid program has added Foundayo as a covered drug in any of the seven preferred drug lists we checked. We found two public review signals: Kansas lists Foundayo on its public “List of Drugs Under Review,” and Mississippi has Foundayo formally on its May 12, 2026 P&T committee agenda under “Antiobesity Select Agents.”

State PDLs distinguish between preferred (easier to approve), non-preferred (covered but requires PA), and not listed at all (non-formulary, usually requires an exception). Being on a PDL does not mean coverage is automatic.

The Foundayo Medicaid Launch Tracker (April 20, 2026)

Why the answer changes by state and plan type (FFS vs. MCO)

Two people on Medicaid in the same state can get different Foundayo answers because most states deliver Medicaid through a mix of fee-for-service (FFS) — the state pays pharmacy claims directly — and managed care organizations (MCOs) — private insurers contracted to manage benefits. MCOs frequently maintain their own formularies that can be stricter, looser, or just different from the state’s public PDL. Roughly 75% of Medicaid enrollees nationally are in MCOs.

How to tell which one you have in 30 seconds

Can your MCO cover Foundayo if the state FFS list doesn’t? Yes, in some cases. When a state’s Uniform PDL applies across MCOs (Minnesota is an example), MCO coverage matches FFS. But in most states, MCOs have some formulary discretion and can cover drugs not on the state’s FFS PDL — especially through non-formulary PA or formulary exception pathways.

Why Medicaid treats Foundayo differently from Ozempic

Under the federal Medicaid Drug Rebate Program, state Medicaid programs must cover nearly all FDA-approved drugs from participating manufacturers — but a short list of drug categories is allowed to be excluded, and “agents when used for weight loss” is one of them. Foundayo is FDA-approved only for chronic weight management, making coverage state-optional. Drugs like Ozempic are mandatory-coverage when prescribed for their FDA-approved diabetes indication.

Can you use the Foundayo Savings Card with Medicaid?

This is written in plain language in the official Foundayo Coverage & Savings terms, and it’s one of the most frustrating parts of being on Medicaid in 2026. You see the “$25/month” figure in ads. You get excited. Then you read the fine print and realize the card was never available to you.

Will the BALANCE Model make Foundayo easier to get through Medicaid?

Eventually, yes — but not automatically and not immediately. CMS’s BALANCE Model allows state Medicaid agencies to opt in to negotiated GLP-1 coverage starting as early as May 2026, on a rolling opt-in window through December 2026. Participation is voluntary at three layers (manufacturer, state, and for Medicare, Part D plan sponsor), and CMS explicitly states coverage is not guaranteed for any individual enrollee.

The BALANCE Model timeline

The practical signal to watch: your state Medicaid agency’s BALANCE opt-in announcement (typically issued as a pharmacy bulletin or a P&T committee decision).

How to check your own Medicaid plan in 10 minutes

If Medicaid says no: the four meanings of “no”

A denial isn’t one thing — it’s four different things, and the right next step depends on which one you got. Before you appeal anything, get the denial reason in writing. This is your right under federal Medicaid rules.

The prior-authorization appeal playbook

If your denial is “prior authorization incomplete” or an MCO criteria issue, you have a real path. Common documentation anchors (confirm specific requirements with your plan in writing first):

For a step-by-step guide to the Foundayo prior authorization process, see: Foundayo Prior Authorization Guide →

If Foundayo specifically won’t work: what’s more likely to be covered today

If you want an oral GLP-1 pill specifically and your state’s Medicaid covers weight-loss drugs, Wegovy tablet (oral semaglutide) is currently the only branded oral obesity GLP-1 we found publicly listed as preferred on 2026 state Medicaid PDLs — specifically in North Carolina (preferred), Kansas (preferred), and Delaware (non-preferred with PA).

We’re not telling you to ask your doctor for a different drug just because it’s easier to get. Foundayo and the Wegovy pill are different medications with different dosing, side-effect profiles, and clinical trial results. But if the question is “which obesity pill am I most likely to actually get covered on Medicaid this year,” the evidence today points to Wegovy tablet in a handful of states.

If Medicaid isn’t going to work — your realistic paths

If your state Medicaid doesn’t cover Foundayo and a formulary exception is unlikely, your realistic choices are: (1) wait for BALANCE in your state, (2) self-pay through LillyDirect, or (3) transition to commercial insurance if your life situation is changing. Here are straight numbers on each.

We won’t pretend $149/month is affordable if you’re on Medicaid. For most Medicaid-income households, it isn’t. But we’d rather tell you the real numbers than route you to a product that isn’t a fit.

LillyDirect self-pay pricing by dose (verified April 2026)

If you’re losing Medicaid coverage soon

If you’re about to lose Medicaid due to post-PHE unwinding, a recertification failure, an income change, or aging out, your Foundayo access strategy shifts from Medicaid navigation to commercial insurance navigation — which typically unlocks the $25/month Savings Card for the first time and opens telehealth routes that currently exclude Medicaid enrollees.

Ro’s free GLP-1 Insurance Coverage Checker runs against your commercial plan’s Foundayo coverage at no cost. Note: Ro does not accept current Medicaid enrollees into Ro Body. This CTA is for readers transitioning to commercial coverage. (Partner link.)

Frequently asked questions

Related guides

• Does Insurance Cover Foundayo? Commercial, Medicare, and Medicaid — for readers with commercial or mixed coverage situations
• Foundayo Prior Authorization Guide — what to ask, what to document, what to appeal
• Does Medicare Cover Foundayo? Bridge & BALANCE Model (2026) — the Medicare-specific pathway separate from Medicaid
• Foundayo Cost Without Insurance: Full Pricing Guide — self-pay pricing for all six doses, every pharmacy route
• Foundayo Patient Assistance Program: 4 Real 2026 Paths — LillyDirect, Savings Card, Medicare Bridge, PAN Foundation
• Foundayo Savings Card 2026: $25, $149, or $349? — commercial insurance lanes (not available to Medicaid)